华东医药：子公司HDM1002片获美国FDA临床试验批准

Core Viewpoint - The company, Huadong Medicine, announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has received approval from the U.S. Food and Drug Administration (FDA) for the clinical trial application of the drug HDM1002, which is intended for weight management in overweight or obese populations [1] Group 1 - Huadong Medicine's subsidiary has successfully obtained FDA approval for HDM1002, marking a significant milestone in its product development [1] - HDM1002 is specifically designed for weight management, targeting the overweight and obese demographic [1]